Since the successful use of the PARP1 inhibitor olaparib in the treatment of cancers caused by BRCA1 and BRCA2 mutations, such as breast, ovarian, pancreatic, and prostate cancers, synthetic lethality-based anticancer therapy has garnered enormous attention [16]. Here, BRCA1 is linked to cancer.